NewAmsterdam Pharma Shares Surge 12.88%, Up 5.90% on Earnings, Trial, Regulatory Advances

NewAmsterdam Pharma (NAMS) surged 12.88% intraday on October 6, 2025, marking its highest share price since October 2025. The stock closed up 5.90%, reflecting renewed investor optimism amid key developments in its pipeline and financial performance.

The rally followed the company’s Q2 2025 earnings report, which highlighted a year-over-year revenue increase to $19.15 million and a narrower net loss compared to the prior year. Analysts cited the results as evidence of early commercial traction, bolstering confidence in the firm’s ability to scale operations and reduce losses.

A critical catalyst was the positive Phase 3 trial data for obicetrapib, NewAmsterdam’s lead candidate. The drug demonstrated significant reductions in Alzheimer’s biomarkers and cardiovascular risk factors, positioning it as a dual-therapeutic option. This outcome reinforced its potential to address overlapping markets, enhancing its scientific and commercial appeal.

Regulatory progress further fueled momentum. The European Medicines Agency accepted the Marketing Authorization Application for obicetrapib, a pivotal step toward EU approval. This decision validated the drug’s potential to meet unmet medical needs and accelerated investor expectations for a favorable regulatory outcome.

Analyst upgrades and strategic collaborations added to the positive sentiment. Upgraded forecasts reflected optimism about the pipeline’s long-term value, while a partnership with Piramal Pharma Solutions aimed to strengthen manufacturing capabilities. These moves addressed operational challenges and signaled the company’s commitment to scaling production efficiently.

Despite the bullish factors, divergent fair value estimates highlight market uncertainty. While some analysts emphasize obicetrapib’s transformative potential, others caution about ongoing losses, cash burn, and competitive pressures in the Alzheimer’s and cardiovascular sectors. The company’s upcoming participation in investor and medical conferences is expected to provide further clarity on its strategic direction and data roadmap.